Cell Source Stock Current Valuation
| CLCS Stock | USD 0.50 0.02 4.17% |
Valuation analysis of Cell Source helps investors to measure Cell Source's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Cell Source's price fluctuation is out of control at this time. Calculation of the real value of Cell Source is based on 3 months time horizon. Increasing Cell Source's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cell otc stock is determined by what a typical buyer is willing to pay for full or partial control of Cell Source. Since Cell Source is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cell OTC Stock. However, Cell Source's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.5 | Real 0.42 | Hype 0.5 | Naive 0.38 |
The intrinsic value of Cell Source's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cell Source's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cell Source helps investors to forecast how Cell otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cell Source more accurately as focusing exclusively on Cell Source's fundamentals will not take into account other important factors: Cell Source OTC Stock Current Valuation Analysis
Cell Source's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cell Source Current Valuation | 59.65 M |
Most of Cell Source's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cell Source is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cell Source has a Current Valuation of 59.65 M. This is 99.58% lower than that of the Healthcare sector and 98.72% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.64% higher than that of the company.
Cell Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cell Source's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cell Source could also be used in its relative valuation, which is a method of valuing Cell Source by comparing valuation metrics of similar companies.Cell Source is currently under evaluation in current valuation category among its peers.
Cell Fundamentals
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Shares Owned By Insiders | 32.13 % | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Net Income | (5.47 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Beta | -64.41 | |||
| Market Capitalization | 10.61 M | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Working Capital | (7.79 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
| Net Asset | 313.77 K |
About Cell Source Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cell Source's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cell Source using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cell Source based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.